Redx Pharma Plc – LSE:REDX.L
Redx Pharma stock price today
Redx Pharma stock price monthly change
Redx Pharma stock price quarterly change
Redx Pharma stock price yearly change
Redx Pharma key metrics
Market Cap | 58.34M |
Enterprise value | 4.09B |
P/E | -5.25 |
EV/Sales | 1722.03 |
EV/EBITDA | -577.22 |
Price/Sales | 16.73 |
Price/Book | 1.19 |
PEG ratio | -0.31 |
EPS | -0.16 |
Revenue | 22.89M |
EBITDA | -49.70M |
Income | -51.16M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -228.93% |
Oper. margin | -322.73% |
Gross margin | 87.62% |
EBIT margin | -322.73% |
EBITDA margin | -217.11% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRedx Pharma stock price history
Redx Pharma stock forecast
Redx Pharma financial statements
| Mar 2022 | 8.35M | -9.76M | -116.88% |
|---|---|---|---|
| Sep 2022 | 10.33M | -8.24M | -79.73% |
| Mar 2023 | 2.31M | -20.76M | -898.57% |
| Sep 2023 | 1.89M | -12.39M | -655.21% |
| 2025 | 1.25M | -49.3M | -3939.27% |
|---|
Analysts Price target
Financials & Ratios estimates
| Mar 2022 | 39940000 | 34.56M | 86.53% |
|---|---|---|---|
| Sep 2022 | 62477000 | 29.15M | 46.67% |
| Mar 2023 | 42848000 | 27.92M | 65.17% |
| Sep 2023 | 25636000 | 22.28M | 86.91% |
| Mar 2022 | 2.58M | -158K | -408K |
|---|---|---|---|
| Sep 2022 | -11.05M | -83K | 33.39M |
| Mar 2023 | -18.66M | -164K | -408K |
| Sep 2023 | -16.07M | -31K | -408K |
Redx Pharma alternative data
| Aug 2023 | 95 |
|---|---|
| Sep 2023 | 95 |
| Oct 2023 | 95 |
| Nov 2023 | 95 |
| Dec 2023 | 95 |
| Jan 2024 | 65 |
| Feb 2024 | 65 |
| Mar 2024 | 101 |
| Apr 2024 | 101 |
| May 2024 | 101 |
| Jun 2024 | 101 |
| Jul 2024 | 101 |
Redx Pharma other data
| Insider | Compensation |
|---|---|
Ms. Lisa Mary Whewell Anson (1970) Chief Executive Officer & Executive Director | $508,370 |
Dr. James Mead (1978) Chief Operating Officer | $195,930 |
-
What's the price of Redx Pharma stock today?
One share of Redx Pharma stock can currently be purchased for approximately $86.
-
When is Redx Pharma's next earnings date?
Unfortunately, Redx Pharma's (REDX.L) next earnings date is currently unknown.
-
Does Redx Pharma pay dividends?
No, Redx Pharma does not pay dividends.
-
How much money does Redx Pharma make?
Redx Pharma has a market capitalization of 58.34M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 77.52% to 4.2M US dollars.
-
What is Redx Pharma's stock symbol?
Redx Pharma Plc is traded on the LSE under the ticker symbol "REDX.L".
-
What is Redx Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Redx Pharma?
Shares of Redx Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Redx Pharma's key executives?
Redx Pharma's management team includes the following people:
- Ms. Lisa Mary Whewell Anson Chief Executive Officer & Executive Director(age: 55, pay: $508,370)
- Dr. James Mead Chief Operating Officer(age: 47, pay: $195,930)
-
How many employees does Redx Pharma have?
As Jul 2024, Redx Pharma employs 101 workers.
-
When Redx Pharma went public?
Redx Pharma Plc is publicly traded company for more then 10 years since IPO on 27 Mar 2015.
-
What is Redx Pharma's official website?
The official website for Redx Pharma is redxpharma.com.
-
How can i contact Redx Pharma?
Redx Pharma can be reached via phone at +44 1625 469900.
Redx Pharma company profile:
Redx Pharma Plc
redxpharma.comLSE
101
Biotechnology
Healthcare
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
Macclesfield, SK10 4TG
:
ISIN: GB00BSNB6S51
CUSIP: G7456P101
